Oxygen Biotherapeutics submits a patent application for its heart attack treatment device

Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that the company has submitted a patent application for a new invention that uses Oxycyte(R) perfluorocarbon to deliver oxygen as a first aid treatment for victims of heart attacks and strokes. Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.

The invention provides an immediate supply of Oxycyte and oxygen to the victim of a heart attack or stroke until medical help is available. It may be easily used by a person who has suffered a heart attack or stroke, but is still conscious, without the assistance of another. It may also be used easily by someone who cannot adequately perform CPR in order to assist someone who is unconscious.

By safely combining Oxycyte and oxygen in a device without pressure, and administering both together with the help of a self-propelled compressor, Oxycyte is able to absorb and carry into the victim's lungs an oxygen load that is 50 times greater than what the same volume of blood is able to carry. The concept of this invention is to administer oxygen-enriched Oxycyte through the lungs to reach oxygen-deprived tissues even when circulation is obstructed and/or a person has stopped breathing.

"This exciting new invention builds on our other intellectual property and gives us a way to leverage even greater value from our key product, Oxycyte. We've already named the invention Vitavent(TM). Ultimately, I see this device being sold over the counter and present wherever there is a defibrillator as well as in any home where there is concern about a potential heart attack or stroke for a loved one," said Chris Stern, company chairman and CEO. "We are already working on the market prototypes and intend to file a new device application with the FDA as soon as possible."

"With Vitavent, we now have a fourth pillar for our business strategy. It joins our cosmetic application, Dermacyte(TM), which we intend to launch in Q4; Wundecyte(TM), our wound care device and application; and our clinical compound Oxycyte, which is now in a Phase II-b clinical trial for Traumatic Brain Injury," said Stern.